icon-folder.gif   Conference Reports for NaTaP  
 
  EASL - The International Liver Congress 2015
50th annual Meeting of the European
association for the Study of the Liver
Vienna, austria  april 22-26
Back grey_arrow_rt.gif
 
 
 
100% SVR12 With Ledipasvir/Sofosbuvir ± Ribavirin for 12 Weeks in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Who Previously Failed Protease Inhibitor + Pegylated Interferon-a + Ribavirin Therapy
 
 
  Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
 
Masao Omata,1 Tetsuo Takehara,2 Osamu Yokosuka,3 Naoya Sakamoto,4 Masaaki Korenaga,5 Hitoshi Mochizuki,1 Kunio Nakane,6 Hirayuki Enomoto,7 Mikio Yanase,5 Hidenori Toyoda,8 Fusao Ikeda,9 Takuya Genda,10 Takeji Umemura,11 Hiroshi Yatsuhashi,12 Tatsuya Ide,13 Nobuo Toda,14 Kazushige Nirei,15
Yoshiyuki Ueno,16 Yoichi Nishigaki,17 Shampa De-Oertel,18 Bing Gao,18 Hadas Dvory-Sobol,18 Akinobu Ishizaki,19 Masa Omote,19 Phillip S. Pang,18 Steven J. Knox,18 William T. Symonds,18 John G. McHutchison,18 Namiki Izumi,20 Masashi Mizokami,5 on behalf of the GS-US-337-0113 Study Team
1Yamanashi Prefectural Hospital Organization, Yamanashi, Japan; 2Osaka University Hospital, Osaka, Japan; 3Chiba University, Chiba, Japan; 4Hokkaido University, Hokkaido, Japan; 5National Center for Global Health and Medicine, Tokyo, Japan; 6Akita City Hospital, Akita, Japan; 7Hyogo College of Medicine, Hyogo, Japan; 8Ogaki Municipal Hospital, Gifu, Japan; 9Okayama University, Okayama, Japan; 10Juntendo University, Tokyo, Japan;
11Shinshu University, Nagano, Japan; 12National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan; 13Kurume University, Fukuoka, Japan; 14Mitsui Memorial Hospital, Tokyo, Japan; 15Nihon University, Tokyo, Japan; 16Yamagata University, Yamagata, Japan; 17Gifu Municipal Hospital, Gifu, Japan; 18Gilead Sciences, Inc., Foster City, California, USA; 19Gilead Sciences KK, Tokyo, Japan; 20Musashino Red Cross Hospital, Tokyo, Japan

EASL1.gif

EASL2.gif

EASL3.gif

EASL4.gif

EASL5.gif

EASL6.gif

EASL7.gif